Comment
Author: Admin | 2025-04-28
D, Gjorgoski I, Krajoska J, Popovska M, Muratovska I, et al. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws. J Craniomaxillofac Surg. 2018;46:230–6.Article PubMed Google Scholar Wu R, Chen H, Chang N, Xu Y, Jiao J, Zhang H. Unlocking the drug potential of the bryostatin family: recent advances in product synthesis and biomedical applications. Chemistry. 2020;26:1166–95.Article CAS PubMed Google Scholar Kollár P, Rajchard J, Balounová Z, Pazourek J. Marine natural products: bryostatins in preclinical and clinical studies. Pharm Biol. 2014;52:237–42.Article PubMed Google Scholar Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321:509–16.Article CAS PubMed Google Scholar Zahid A, Li B, Kombe AJK, Jin T, Tao J. Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 2019;10:2538.Article PubMed PubMed Central Google Scholar Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736–45.Article CAS PubMed PubMed Central Google Scholar Guo W, Chen S, Li C, Xu J, Wang L. Application of disulfiram and its metabolites in treatment of inflammatory disorders. Front Pharmacol. 2022;12:795078.Article PubMed PubMed Central Google Scholar Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med. 1990;88:647–55.Article CAS PubMed Google Scholar Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I,
Add Comment